Hereditary Angioedema
📧 Sign up to get email alerts when something new happens for Hereditary Angioedema.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2014-07-25Clinical Trial Update: CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 [Phase 2]
Phase 2 trial update for CINRYZE in children under 12 with hereditary angioedema has completed with results posted.
-
CLINICAL_TRIALS research · 2014-06-10Clinical Trial Update: Hereditary AngioEdema, Neurobiology and Psychopathology
This clinical trial update from University Hospital, Catania reports research into hereditary angioedema with neurobiological and psychopath…
-
CLINICAL_TRIALS trial_result · 2014-06-09Clinical Trial Update: Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE) [Phase 3]
Phase 3 trial update of subcutaneous icatibant for acute attacks in hereditary angioedema; results posted after completion.
-
CLINICAL_TRIALS research · 2014-06-09Clinical Trial Update: Patient Registry Study of Berinert® in Normal Clinical Practice
A completed patient registry study assessing the use of Berinert (C1 esterase inhibitor) in normal clinical practice for hereditary angioede…
-
FDA approval · 2014-03-28FDA Approved: KALBITOR — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Kalbitor (ecallantide) submitted by Takeda Pharmaceuticals America, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-12-24Clinical Trial Update: Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema [Phase 3]
Phase 3 trial update evaluating subcutaneous icatibant for acute attacks of hereditary angioedema has completed with results posted.
-
FDA approval · 2013-08-30FDA Approved: FIRAZYR — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Firazyr (icatibant acetate) from Takeda Pharmaceuticals America, Inc., resulting in changes to t…
-
CLINICAL_TRIALS trial_result · 2013-07-18Clinical Trial Update: A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE [Phase 4]
Phase 4 trial evaluating escalating doses of CINRYZE for hereditary angioedema has completed with results posted in 2013.
-
CLINICAL_TRIALS trial_result · 2013-04-25Clinical Trial Update: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema [Phase 2]
A Phase 2 study evaluating recombinant human C1 inhibitor for acute attacks in hereditary angioedema has completed.
-
FDA approval · 2013-04-10FDA Approved: KALBITOR — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Kalbitor (ecallantide) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2013-04-05Clinical Trial Update: A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor [Phase 1]
A Phase 1 study completed evaluating the safety and pharmacokinetics of two formulations of C1-esterase inhibitor for hereditary angioedema,…
-
CLINICAL_TRIALS trial_result · 2013-02-22Clinical Trial Update: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema [Phase 2, Phase 3]
Clinical trial update on recombinant human C1 inhibitor (Ruconest) for acute attacks in hereditary angioedema, covering Phase 2/3 studies wi…
-
CLINICAL_TRIALS trial_result · 2013-01-31Clinical Trial Update: A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration [Phase 2]
Phase 2 results report safety and immunogenicity of repeated administration of recombinant human C1 esterase inhibitor in hereditary angioed…
-
FDA approval · 2013-01-28FDA Approved: FIRAZYR — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approves a supplemental application for FIRAZYR (icatibant acetate) from Takeda Pharmaceuticals America, expanding/updating its appr…
-
CLINICAL_TRIALS trial_result · 2013-01-04Clinical Trial Update: A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase [Phase 2]
Phase 2 study evaluating safety and pharmacology of subcutaneous CINRYZE with recombinant human hyaluronidase in hereditary angioedema has c…
-
CLINICAL_TRIALS trial_result · 2012-12-28Clinical Trial Update: Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE) [Phase 3]
Phase 3 trial update evaluating repeated doses of ecallantide (DX-88) for treatment of attacks in hereditary angioedema (HAE).
-
CLINICAL_TRIALS withdrawal · 2012-11-30Clinical Trial Update: C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation [Phase 4]
Phase 4 trial comparing C1 esterase inhibitor to placebo at prodromal symptoms for hereditary angioedema has been withdrawn.
-
FDA approval · 2012-11-28FDA Approved: FIRAZYR — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for FIRAZYR (icatibant acetate) by Takeda Pharmaceuticals America, Inc., approving a supplement …
-
CLINICAL_TRIALS trial_result · 2012-08-31Clinical Trial Update: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema [Phase 2, Phase 3]
Complete Phase 2 and Phase 3 trial updates for recombinant human C1 esterase inhibitor in treating acute attacks of hereditary angioedema, w…
-
CLINICAL_TRIALS trial_result · 2012-08-30Clinical Trial Update: Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema [Phase 3]
Phase 3 trial evaluating recombinant human C1 esterase inhibitor for acute attacks in hereditary angioedema has completed with results poste…
-
FDA approval · 2012-04-24FDA Approved: KALBITOR — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Kalbitor (ecallantide) from Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2012-03-19FDA Approved: DANAZOL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for danazol from Teva Pharmaceuticals USA, Inc. The approval updates the drug's labeling and/or indi…
-
CLINICAL_TRIALS trial_result · 2012-03-08Clinical Trial Update: A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration [Phase 2]
Phase 2 trial update evaluating safety, PK, and PD of subcutaneous CINRYZE in hereditary angioedema has completed with posted results.
-
FDA approval · 2011-08-25FDA Approved: FIRAZYR — Original Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved Firazyr (icatibant acetate) from Takeda Pharmaceuticals America, Inc. for the acute treatment of hereditary angioedema atta…
-
FDA approval · 2011-08-17FDA Approved: KALBITOR — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Kalbitor (ecallantide) from Takeda Pharmaceuticals America, Inc. The action updates the product'…